Belçika - Hollandaca - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires belges pharmacobel sa-nv - magnesiumcarbonaat 114 mg; kaolien (zwaar) 30 mg; magnesiumtrisilicaat 20 mg; calciumcarbonaat 160 mg - kauwtablet - 10 mg - 3,5 g - 12 g - kaolien 30 mg; magnesiumcarbonaat 114 mg; magnesiumtrisilicaat 20 mg; calciumcarbonaat 160 mg - ordinary salt combinations

Hollanda - Hollandaca - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

glenmark arzneimittel gmbh industriestrasse 31 82194 grobenzell (duitsland) - ursodeoxycholzuur-- 250 mg/stuk - capsule, hard - crospovidon (e 1202) ; gelatine (e 441) ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat ; siliciumdioxide (e 551) ; titaandioxide (e 171) ; zetmeel, gepregelatineerd ; zonnegeel fcf (e 110), crospovidon (e 1202) ; gelatine (e 441) ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat (e 487) ; siliciumdioxide (e 551) ; titaandioxide (e 171) ; zetmeel, gepregelatineerd ; zonnegeel fcf (e 110), - ursodeoxycholic acid

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. onsets van immuniteit zijn aangetoond een week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus, chlamydophila felis en panleucopenie componenten. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp1338-virus - immunostimulants, antineoplastische en immunomodulerende middelen, immunostimulants, - cats - immunotherapie voor gebruik in combinatie met chirurgie en radiotherapie bij katten met fibrosarcoom (diameter 2-5 cm) zonder betrokkenheid van metastasen of lymfeklieren, om het risico van terugval te verminderen en de tijd tot terugval te verlengen (lokaal recidief of metastase).

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - cats - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. het diergeneesmiddel is uitsluitend geïndiceerd bij alle drie de groepen zijn gericht op hetzelfde moment.

Avrupa Birliği - Hollandaca - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosuppressiva - raadpleeg het document met productinformatie.